Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Large Growth in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 457,500 shares, a growth of 90.3% from the December 15th total of 240,400 shares. Based on an average daily trading volume, of 3,640,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 3.2% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, Maxim Group reaffirmed a “hold” rating on shares of Virpax Pharmaceuticals in a report on Wednesday, October 9th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC bought a new stake in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned approximately 1.17% of Virpax Pharmaceuticals at the end of the most recent reporting period. 32.23% of the stock is currently owned by institutional investors.

Virpax Pharmaceuticals Stock Down 2.0 %

Shares of VRPX opened at $0.35 on Wednesday. Virpax Pharmaceuticals has a 12 month low of $0.29 and a 12 month high of $5.48. The stock’s 50-day moving average price is $0.45 and its two-hundred day moving average price is $0.73.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.